Hydrochloric Acid

Hydrochloric Acid

SCHEMBL465434

CCCCC[S+](CCCCC)CCCCC.[Cl-]

nearest known ligand 0.47

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA

The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
TSHR P16473 5/20 0.47
THRB P10828 1/20 0.47
LMNA P02545 3/20 0.40
SLC22A1 O15245 3/20 0.37
SLC22A2 O15244 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
DNM1 Q05193 5/20 0.36
ALDH1A1 P00352 3/20 0.35
HSD17B10 Q99714 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL4463624 0.97 TSHR (0.53) TSHRTHRBLMNASLC22A1DNM1
Hydrochloric Acid SCHEMBL11672231 0.97 TSHR (0.53) TSHRTHRBLMNASLC22A1DNM1
Hydrochloric Acid SCHEMBL11672430 0.97 TSHR (0.53) TSHRTHRBLMNASLC22A1DNM1
Hydrochloric Acid SCHEMBL11619467 0.97 TSHR (0.53) TSHRTHRBLMNASLC22A1DNM1
Hydrochloric Acid SCHEMBL11672035 0.97 TSHR (0.53) TSHRTHRBLMNASLC22A1DNM1
Hydrochloric Acid SCHEMBL11671892 0.97 TSHR (0.53) TSHRTHRBLMNASLC22A1DNM1
SCHEMBL39345 0.96 TSHR (0.50) TSHRTHRBLMNASLC22A1SLC22A2
SCHEMBL3791346 0.93 TSHR (0.57) TSHRTHRBLMNASLC22A1DNM1
SCHEMBL3199493 0.93 TSHR (0.57) TSHRTHRBLMNASLC22A1DNM1
SCHEMBL4238292 0.93 TSHR (0.47) TSHRTHRBLMNASLC22A1SLC22A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 263 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110231754-B Heterocyclic multifunctional photoinduced acid generator, preparation method thereof and prepared chemical amplification type photoresist 苏州瑞红电子化学品有限公司 2023-05-02 CN claimed
EP-3844239-A1 USE OF SULFONIUM SALTS AS CORROSION INHIBITORS ChampionX USA Inc. (US) 2021-07-07 EP claimed
US-10900128-B2 Use of sulfonium salts as corrosion inhibitors CHAMPIONX USA INC. (US) 2021-01-26 US claimed
CN-111302979-A Single-component molecular glass and preparation method and application thereof 苏州瑞红电子化学品有限公司 2020-06-19 CN claimed
EP-1347012-B2 Curable Fluoroelastomers SOLVAY SPECIALTY POLYMERS IT (IT) 2020-04-29 EP claimed
WO-2020047193-A1 USE OF SULFONIUM SALTS AS CORROSION INHIBITORS ECOLAB USA INC. (US) 2020-03-05 WO claimed
US-20200071840-A1 USE OF SULFONIUM SALTS AS CORROSION INHIBITORS HARBISON-FISCHER, INC. 2020-03-05 US claimed
US-20180245004-A1 USE OF SULFONIUM SALTS AS HYDROGEN SULFIDE INHIBITORS CHAMPIONX LLC 2018-08-30 US claimed
US-7767764-B2 Fluoroelastomers SOLVAY SOLEXIS S.P.A. (IT) 2010-08-03 US claimed
US-7705083-B2 blends comprising vinylidene fluoride copolymer can be curable by ionic route, accelerator, curing agent; low compression set values; improved sealing properties; improved compression set on O-ring SOLVAY SOLEXIS S.P.A. (IT) 2010-04-27 US claimed
EP-1347012-B1 Curable Fluoroelastomers SOLVAY SOLEXIS SPA (IT) 2006-12-20 EP claimed
US-20050245691-A1 Curable fluoroelastomers SOLVAY SOLEXIS S.P.A. 2005-11-03 US claimed
EP-1591479-A1 Curable Fluorelastomers Solvay Solexis S.p.A. (IT) 2005-11-02 EP claimed
US-6664338-B2 Polymer curable by ionic route comprising fluoroelastomer based on vinylidene fluoride having amount of polar end group lower than 3% by moles, accelerant, curing agent, inorganic acid acceptors, basic compounds, reinforcing fillers AUSIMONT S.P.A. (IT) 2003-12-16 US claimed
US-20030187144-A1 Curable fluoroelastomers AUSIMONT S.P.A. 2003-10-02 US claimed
EP-1347012-A2 Curable Fluoroelastomers Solvay Solexis S.p.A. (IT) 2003-09-24 EP claimed
EP-0833857-B1 IMPROVED SCORCH SAFETY OF CURABLE FLUOROELASTOMER COMPOSITIONS DYNEON LLC (US) 2002-07-24 EP claimed
US-5756588-A CURABLE COMPOSITION COMPRISING FLUOROPOLYMER, AROMATIC POLYHYDROXY CROSSLINKING AGENT, ORGANO-ONIUM COMPOUND, MONOHYDROXYFUNCTIONAL PHENOL CAPABLE OF DELAYING POST-COMPOUNDING INITIATION MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1998-05-26 US claimed
EP-0833857-A1 IMPROVED SCORCH SAFETY OF CURABLE FLUOROELASTOMER COMPOSITIONS DYNEON LLC (US) 1998-04-08 EP claimed
WO-1997000906-A1 IMPROVED SCORCH SAFETY OF CURABLE FLUOROELASTOMER COMPOSITIONS DYNEON LLC (US) 1997-01-09 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180245004-A1 USE OF SULFONIUM SALTS AS HYDROGEN SULFIDE INHIBITORS STS, TST, ARSA TSHR 1433/4885THRB 1526/4885LMNA 4873/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.